Patient demographic and disease characteristics in the ITT population
| . | D-R . | R . |
|---|---|---|
| Age, y | n = 99 | n = 101 |
| Median (range) | 63 (35-77) | 62 (35-78) |
| Category, n (%) | ||
| <65 | 61 (61.6) | 61 (60.4) |
| 65-70 | 23 (23.2) | 21 (20.8) |
| ≥70 | 15 (15.2) | 19 (18.8) |
| Sex, n (%) | n = 99 | n = 101 |
| Male | 61 (61.6) | 58 (57.4) |
| Female | 38 (38.4) | 43 (42.6) |
| Race, n (%) | n = 99 | n = 101 |
| White | 67 (67.7) | 68 (67.3) |
| Black or African American | 20 (20.2) | 24 (23.8) |
| Asian | 5 (5.1) | 1 (1.0) |
| American Indian or Alaska native | 0 | 1 (1.0) |
| Other∗ | 5 (5.1) | 5 (5.0) |
| Not reported | 2 (2.0) | 2 (2.0) |
| ECOG PS score, n (%) | n = 99 | n = 101 |
| 0 | 45 (45.5) | 55 (54.5) |
| 1 | 52 (52.5) | 44 (43.6) |
| 2 | 2 (2.0) | 2 (2.0) |
| ISS disease stage, n (%) | n = 91 | n = 98 |
| I | 40 (44.0) | 38 (38.8) |
| II | 28 (30.8) | 37 (37.8) |
| III | 23 (25.3) | 23 (23.5) |
| No. of induction cycles | n = 98 | n = 99 |
| Median (range) | 5.0 (4.0-8.0) | 5.0 (4.0-8.0) |
| Cytogenetic risk at diagnosis | n = 92 | n = 89 |
| Standard risk | 63 (68.5) | 66 (74.2) |
| High risk† | 22 (23.9) | 15 (16.9) |
| del(17p) | 13 (14.1) | 3 (3.4) |
| t(4;14) | 10 (10.9) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| Unknown | 7 (7.6) | 8 (9.0) |
| Revised cytogenetic risk at diagnosis | n = 93 | n = 89 |
| Standard risk | 52 (55.9) | 53 (59.6) |
| High risk‡ | 32 (34.4) | 30 (33.7) |
| del(17p) | 13 (14.0) | 3 (3.4) |
| t(4;14) | 10 (10.8) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| t(14;20) | 1 (1.1) | 2 (2.2) |
| gain/amp(1q21) | 16 (17.2) | 22 (24.7) |
| Unknown | 9 (9.7) | 6 (6.7) |
| . | D-R . | R . |
|---|---|---|
| Age, y | n = 99 | n = 101 |
| Median (range) | 63 (35-77) | 62 (35-78) |
| Category, n (%) | ||
| <65 | 61 (61.6) | 61 (60.4) |
| 65-70 | 23 (23.2) | 21 (20.8) |
| ≥70 | 15 (15.2) | 19 (18.8) |
| Sex, n (%) | n = 99 | n = 101 |
| Male | 61 (61.6) | 58 (57.4) |
| Female | 38 (38.4) | 43 (42.6) |
| Race, n (%) | n = 99 | n = 101 |
| White | 67 (67.7) | 68 (67.3) |
| Black or African American | 20 (20.2) | 24 (23.8) |
| Asian | 5 (5.1) | 1 (1.0) |
| American Indian or Alaska native | 0 | 1 (1.0) |
| Other∗ | 5 (5.1) | 5 (5.0) |
| Not reported | 2 (2.0) | 2 (2.0) |
| ECOG PS score, n (%) | n = 99 | n = 101 |
| 0 | 45 (45.5) | 55 (54.5) |
| 1 | 52 (52.5) | 44 (43.6) |
| 2 | 2 (2.0) | 2 (2.0) |
| ISS disease stage, n (%) | n = 91 | n = 98 |
| I | 40 (44.0) | 38 (38.8) |
| II | 28 (30.8) | 37 (37.8) |
| III | 23 (25.3) | 23 (23.5) |
| No. of induction cycles | n = 98 | n = 99 |
| Median (range) | 5.0 (4.0-8.0) | 5.0 (4.0-8.0) |
| Cytogenetic risk at diagnosis | n = 92 | n = 89 |
| Standard risk | 63 (68.5) | 66 (74.2) |
| High risk† | 22 (23.9) | 15 (16.9) |
| del(17p) | 13 (14.1) | 3 (3.4) |
| t(4;14) | 10 (10.9) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| Unknown | 7 (7.6) | 8 (9.0) |
| Revised cytogenetic risk at diagnosis | n = 93 | n = 89 |
| Standard risk | 52 (55.9) | 53 (59.6) |
| High risk‡ | 32 (34.4) | 30 (33.7) |
| del(17p) | 13 (14.0) | 3 (3.4) |
| t(4;14) | 10 (10.8) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| t(14;20) | 1 (1.1) | 2 (2.2) |
| gain/amp(1q21) | 16 (17.2) | 22 (24.7) |
| Unknown | 9 (9.7) | 6 (6.7) |
ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; ITT, intent to treat.
Patients reporting multiple races are included under “other.”
High risk is defined as positive for any of del(17p), t(14;16), or t(4;14).
Revised high-risk cytogenetics is defined as ≥1 abnormality from del(17p), t(4;14), t(14;16), t(14;20), and gain/amp(1q21).